VanEck Associates’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

VanEck Associates’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-13,368	Closed	-$2.31M	–	857
2015 Q1	$2.31M	Buy	13,368 +1,267	+10%	+$186K	0.01%	345
2014 Q4	$1.39M	Sell	12,101 -249	-2%	-$30.2K	0.01%	392
2014 Q3	$1.93M	Sell	12,350 -674	-5%	-$97.7K	0.01%	339
2014 Q2	$1.61M	Sell	13,024 -2,319	-15%	-$256K	0.01%	369
2014 Q1	$1.59M	Sell	15,343 -7,184	-32%	-$736K	0.01%	343
2013 Q4	$2.03M	Sell	22,527 -4,856	-18%	-$387K	0.01%	317
2013 Q3	$1.83M	Buy	27,383 +4,176	+18%	+$288K	0.01%	320
2013 Q2	$1.53M	Buy	+23,207	New	+$1.33M	0.01%	318

Other funds holding SLXP

MMG

Monetary Management Group St Louis, Missouri $419M AUM 29.55% 1-Year Est. Return

VanEck Associates's SLXP Position: Q2 2015 in Review

VanEck Associates sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2015, closing a stake of 13,368 shares — an estimated $2.31M sold.

VanEck Associates first reported a position in SLXP in Q2 2013 and held it in 8 quarters. The position peaked at $2.31M in Q1 2015. 1 fund tracked by Wall St. Rank holds SLXP as of Q2 2015.

VanEck Associates reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2015 after selling out during the quarter.
VanEck Associates sold 13,368 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2015, an estimated $2.31M.
VanEck Associates first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 8 quarters.
VanEck Associates's SALIX PHARMACEUTICALS LTD DEL position peaked at $2.31M in Q1 2015.
1 fund tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2015.

Based on VanEck Associates's 13F filing for Q2 2015, filed 12 Aug 2015.